We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

X4 Pharmaceuticals Inc (XFOR) NPV

Sell:$4.00 Buy:$4.04 Change: $0.14 (3.37%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Sell:$4.00
Buy:$4.04
Change: $0.14 (3.37%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Sell:$4.00
Buy:$4.04
Change: $0.14 (3.37%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases including primary immunodeficiencies and cancer. The Company’s lead product candidate, mavorixafor, is an oral inhibitor of CXCR4 and is in the clinical trial for the treatment of WHIM syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

Contact details

Address:
61 NORTH BEACON STREET, 4TH FLOOR
BOSTON
02134
United States
Telephone:
+1 (857) 5298300
Website:
www.x4pharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XFOR
ISIN:
US98420X1037
Market cap:
$110.45 million
Shares in issue:
24.71 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Paula Ragan
    President, Chief Executive Officer, Corporate Secretary, Director
  • Adam Mostafa
    Chief Financial Officer, Treasurer
  • Mary Dibiase
    Chief Operating Officer
  • Arthur Taveras
    Chief Scientific Officer
  • Karolyn Park
    Vice President - U.S. Commercial
  • Derek Meisner
    General Counsel
  • Diego Cadavid
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.